BIOMAT Database Logo BIOMAT Database Logo

Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults. 2006

Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA. temesgen.zelalem@mayo.edu

Despite dramatic declines in HIV-associated morbidity and mortality as a result of highly active antiretroviral therapy, management of heavily treatment-experienced patients remains complex and challenging. Treatment response rates with subsequent antiretroviral regimens are lower than with initial antiretroviral therapy. Additionally, increased mortality has been associated with multidrug-resistant HIV. We review data relevant to management of such patients and offer a systematic approach to constructing a salvage antiretroviral regimen.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017211 Treatment Failure A measure of the quality of health care by assessment of unsuccessful results of management and procedures used in combating disease, in individual cases or series. Failure, Treatment,Failures, Treatment,Treatment Failures
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral

Related Publications

Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
Treatment of heavily antiretroviral-experienced HIV-infected patients.
January 2007, AIDS reviews,
Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options.
November 2020, AIDS (London, England),
Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
Salvage antiretroviral therapy in HIV infection.
February 2002, Expert opinion on pharmacotherapy,
Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
Interleukin-2 as an adjunct to antiretroviral therapy for HIV-positive adults.
May 2017, The Cochrane database of systematic reviews,
Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
HIV: how to manage heavily treatment-experienced patients.
January 2022, Drugs in context,
Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
July 2004, HIV medicine,
Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients.
February 2002, Sexually transmitted infections,
Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration.
July 2020, AIDS (London, England),
Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
An aggressive approach to HIV antiretroviral therapy.
January 1998, Hospital practice (1995),
Zelalem Temesgen, and Francesca Cainelli, and Eric M Poeschla, and Stacey A R Vlahakis, and Sandro Vento
Optimizing Antiretroviral Therapy in Heavily ART-Experienced Patients with Multi-Class Resistant HIV-1 Using Proviral DNA Genotypic Resistance Testing.
June 2023, Viruses,
Copied contents to your clipboard!